Art. -Nr.: HY-16929

Latrunculin A

(Synonyms: LAT-A)

12 Cited Publications

Kundenbewertung

Based on 12 publication(s) in Google Scholar

Latrunculin A (LAT-A), found in the red sea sponge Latrunculia magnifica, is a G-actin polymerization inhibitor. Latrunculin A binds to actin monomers and inhibits polymerization of actin with K_ds of 0.1, 0.4, 4.7 μM and 0.19 μM for ATP-actin, ADP-Pi-actin, ADP-actin and G-actin, respectively. Latrunculin A has effective anti-metastatic properties for cancer research. Latrunculin A blocks cell migration.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 98.9%
CAS. Nr.: 76343-93-6
Formel: C₂₂H₃₁NO₅S
Molecular Weight:421.55

Speicherung:

Solution, -20°C, 2 years

Latrunculin A Chemical Structure

CAS. Nr.: 76343-93-6

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (12)
Reinheit & Dokumentation
Verweise
Calculators
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

Kd: 0.1 μM (ATP-actin), 0.4 μM (ADP-Pi-actin), 4.7 μM (ADP-actin), 0.19 μM (G-actin)^[2]

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	0.06 μg/mL Compound: 1	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 8350092]
HCT-116	IC₅₀	1.1 μM Compound: 1, NSC-613011	Cytotoxicity against human HCT116 cells after 3 days by trypan blue assay Cytotoxicity against human HCT116 cells after 3 days by trypan blue assay	[PMID: 18942825]
HT-29	IC₅₀	0.06 μg/mL Compound: 1	Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay	[PMID: 8350092]
HT-29	IC₅₀	0.08 μg/mL Compound: 10	Antiproliferative activity against human HT-29 cells assessed as cell viability after 96 hrs by CellTiter-Glo luminescence assay Antiproliferative activity against human HT-29 cells assessed as cell viability after 96 hrs by CellTiter-Glo luminescence assay	[PMID: 22129061]
MCF7	IC₅₀	0.48 μM Compound: 99a	Anticancer activity against human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Anticancer activity against human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 33940466]
MDA-MB-231	IC₅₀	4.19 μM Compound: 99a	Anticancer activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Anticancer activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 33940466]
MDA-MB-435	IC₅₀	0.04 μg/mL Compound: 10	Antiproliferative activity against human MDA-MB-435 cells assessed as cell viability after 96 hrs by CellTiter-Glo luminescence assay Antiproliferative activity against human MDA-MB-435 cells assessed as cell viability after 96 hrs by CellTiter-Glo luminescence assay	[PMID: 22129061]
MDA-MB-435	IC₅₀	2.8 μM Compound: 1, NSC-613011	Cytotoxicity against human MDA-MB-435 cells 48 hrs by SRB assay Cytotoxicity against human MDA-MB-435 cells 48 hrs by SRB assay	[PMID: 18942825]
P388	IC₅₀	4.1 μg/mL Compound: 1	Cytotoxicity against mouse P388 cells after 48 hrs by MTT assay Cytotoxicity against mouse P388 cells after 48 hrs by MTT assay	[PMID: 8350092]
P388	IC₅₀	4.1 μg/mL Compound: Latrunculin A	Antiproliferative activity against mouse P388 cells Antiproliferative activity against mouse P388 cells	10.1021/np50082a019
T47D	IC₅₀	25 μM Compound: 1,Latrunculin A	Inhibition of 1,10-phenanthroline-induced HIF1 activation in human T47D cells by cell based reporter gene assay Inhibition of 1,10-phenanthroline-induced HIF1 activation in human T47D cells by cell based reporter gene assay	[PMID: 18298079]
T47D	IC₅₀	6.7 μM Compound: 1,Latrunculin A	Inhibition of hypoxia-induced HIF1 activation in human T47D cells by cell based reporter gene assay Inhibition of hypoxia-induced HIF1 activation in human T47D cells by cell based reporter gene assay	[PMID: 18298079]
U-937	IC₅₀	0.07 μg/mL Compound: 10	Antiproliferative activity against human U937 cells assessed as cell viability after 96 hrs by CellTiter-Glo luminescence assay Antiproliferative activity against human U937 cells assessed as cell viability after 96 hrs by CellTiter-Glo luminescence assay	[PMID: 22129061]

In Vitro

Latrunculin A (50-1000 nM) exhibits potent anti-invasive activity against human prostate cancer PC-3M cells, inhibits PC-3M-CT+ spheroids disaggregation and cell migration^[3].
? Latrunculin A (3-30 μM) inhibits hypoxia-induced HIF-1 activation with an IC₅₀ value of 6.7 μM in human breast carcinoma T47D cells^[3].
? Latrunculin A (0-0.2 μM, 4 hours) has a significant inhibitory effect on HuR levels at high concentrations such as 0.2 μM in human hepatoma HepG2 cells while inhibits HuR only at 0.02 μM but no inhibitory effect at high concentrations in human hepatoma Huh7 cells^[4].
? Latrunculin A (0.1 μM, 24 hours) can lead to a significant decrease in cell migration and has an inhibitory effect on cell proliferation in human hepatoma cell lines HepG2^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Latrunculin A (intraperitoneal injection, 0.05 mg/kg, three doses in the first 20 days, 120 days) has strong antitumor effect in male BALB/c nude mice models infected with adenocarcinoma (MKN45) or carcinoma (NUGC-4)^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Male BALB/c nude mice models infected with adenocarcinoma (MKN45) or carcinoma (NUGC-4)^[5]
Dosage:

0.05 mg/kg
Administration:

Intraperitoneal injection; three doses in the first 20 days; 120 days
Result:

Extended the mean life expectancy to 23.5 days comparing to control of 16 days in adenocarcinoma (MKN45) mice and the mean survival time was 42 days comparing to untreated of 31 days in carcinoma (NUGC-4) mice.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 76343-93-6
Appearance Liquid
Molecular Weight 421.55
Formel C₂₂H₃₁NO₅S
Color Colorless to light yellow
SMILES

O=C1SC[C@@H]([C@]2(O)O[C@]3([H])CC[C@H](C)/C=C\C=C\CC/C(C)=C\C(O[C@@](C3)([H])C2)=O)N1
Synonyms

LAT-A
Structure Classification
- Antibiotics
- Macrolide Antibiotics
Initial Source
- Marine natural products
- Sponge
- Animals
red sea sponge Latrunculia magnifica
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

Solution, -20°C, 2 years

Publications (12)

All Flow CytometryELISACell Imaging/StainingIn Vivo Efficacy Study

Sort by:

Journal Impact Factor

Nat Commun

Graphdiyne oxide nanosheets display selective anti-leukemia efficacy against DNMT3A-mutant AML cells. [Abstract]

2022 Sep 26;13(1):5657. PMID: 36163326
J Extracell Vesicles

CD73 in small extracellular vesicles derived from HNSCC defines tumour-associated immunosuppression mediated by macrophages in the microenvironment. [Abstract]

2022 May;11(5):e12218. PMID: 35524455
Adv Sci (Weinh)

Synthetic Retinoid Kills Drug-Resistant Cancer Stem Cells via Inducing RARγ-Translocation-Mediated Tension Reduction and Chromatin Decondensation. [Abstract]

2022 Aug 28;e2203173. PMID: 36031407

Latrunculin A purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2022 Aug 28;e2203173. [Abstract]

The sEVs (50 μg) were cocultured with macrophages (1 × 106) for 24 h. The sEVs^HNSCC derived from two HNSCC lines: SCC25 and HN6. The sEVsh^BMSC-NT5EOE derived from hBMSC cells with NT5E overexpression. Latrunculin A (Lat A, 30 μM; 24 h) was used as the inhibitor of sEVs uptaken showed downregulated phagocytosis. The percentage of pHrodo dyes of M2 macrophages was analyzed by flow cytometry.

Latrunculin A purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2022 Aug 28;e2203173. [Abstract]

The expression of cytokines also increased when macrophages were cocultured with sEVs derived from hBMSCs overexpressing CD73, whereas this trend was reversed by Latrunculin A (Lat A, 30 μM; 24 h).

Latrunculin A purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2022 Aug 28;e2203173. [Abstract]

Macrophages were cocultured with anti-CD73-FITC labelled sEVs from HNSCC cell lines control or RABAKO, CD73-GFP labelled sEVs from hBMSC treated with or without Latrunculin A (Lat A, 30 μM; 24 h) were cocultured with macrophages for 1 h, and Laser Scanning Confocal Microscopy was used to analyze the internalization of HNSCC-derived sEVs into macrophages (Scale bar = 25 μm).

Latrunculin A purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2022 Aug 28;e2203173. [Abstract]

Absence of CD73 in sEVs rescues immune suppression and restrains tumour growth in C3H/He mice aged 6–8 weeks. (a) Schematic of subcutaneous tumorigenesis in vivo experiment, followed with intratumoral injection of sEVs which were collected from SCC7, SCC7-Nt5eKO or SCC7-Nt5eOE cells grown in vitro. (b) The exhibition of isolated tumours. (c and d) The tumour weight and the time course of tumour growth in grams for 15 days postinjection with SCC7 or SCC7Rab27aKO cells with or without CD73 in sEVs. Latrunculin A (Lat A, 0.15 mg/kg; ip; every 2 days for 15 days) was used as inhibitor of sEVs uptaken.

Latrunculin A purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2022 Aug 28;e2203173. [Abstract]

Latrunculin A (Lat A, 0.15 mg/kg; ip; every 2 days for 15 days) was used as an inhibitor of sEVs uptake in C3H/He mice aged 6–8 weeks. Flow cytometry analysis for infiltration of Tregs and percentage of CD73+/PD-1+ Tregs in tumours.
Carbon

2025 Dec 22;248:121179.
Apoptosis

TFAM-Mediated mitochondrial transfer of MSCs improved the permeability barrier in sepsis-associated acute lung injury. [Abstract]

2023 Aug;28(7-8):1048-1059. PMID: 37060506
Ecotoxicol Environ Saf

Lead-induced actin polymerization aggravates neutrophil extracellular trap formation and contributes to vascular inflammation. [Abstract]

2024 Dec 24:290:117598. PMID: 39721424
Talanta

Super-resolution imaging of folate receptor alpha on cell membranes using peptide-based probes. [Abstract]

2024 Feb 1;268(Pt 1):125286. PMID: 37832456
PLoS Pathog

PRRSV-2 impedes lysosomes from eliminating secondary infected bacteria. [Abstract]

2026 Feb 27;22(2):e1014000. PMID: 41758870
mBio

PRRSV promotes bacterial infection by remodeling actin cytoskeleton and cell membrane proteins. [Abstract]

2025 Oct 8;16(10):e0194525. PMID: 40937850
Exp Cell Res

Mechanical stretch promotes the migration of mesenchymal stem cells via Piezo1/F-actin/YAP axis. [Abstract]

2025 Feb 21;446(1):114461. PMID: 39988125
New J Chem

2023 Jun 28.
bioRxiv

2023 Feb 5.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (279 KB)
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Fujiwara I, et al. Latrunculin A Accelerates Actin Filament Depolymerization in Addition to Sequestering Actin Monomers. Curr Biol. 2018 Oct 8;28(19):3183-3192.e2. [Content Brief]

[2]. Coué M, et al. Inhibition of actin polymerization by latrunculin A. FEBS Lett. 1987 Mar 23;213(2):316-8. [Content Brief]

[3]. Khalid A El Sayed, et al. Latrunculin A and its C-17-O-carbamates inhibit prostate tumor cell invasion and HIF-1 activation in breast tumor cells. J Nat Prod. 2008 Mar;71(3):396-402. [Content Brief]

[4]. Anke Doller, et al. The cytoskeletal inhibitors latrunculin A and blebbistatin exert antitumorigenic properties in human hepatocellular carcinoma cells by interfering with intracellular HuR trafficking. Exp Cell Res. 2015 Jan 1;330(1):66-80. [Content Brief]

[5]. Hiroo Konishi, et al. Latrunculin a has a strong anticancer effect in a peritoneal dissemination model of human gastric cancer in mice. Anticancer Res. 2009 Jun;29(6):2091-7. [Content Brief]

[6]. Liang Ma, et al. Discovery of the migrasome, an organelle mediating release of cytoplasmic contents during cell migration. Cell Res. 2015 Jan;25(1):24-38. [Content Brief]

Calculators

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

Latrunculin A

12 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Latrunculin A

Publications Citing Use of MedChemExpress (MCE) Latrunculin A

Biologische Aktivität

Chemical Information

Publications (12)

Reinheit & Dokumentation

Verweise

Calculators

Help & FAQs

Latrunculin A Related Classifications

HY-16929 Related Classifications